KLRS

+ Watchlist + Portfolio

Kalaris Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.17
52-Week Range: $2.37 – $11.88
Market Cap: $98.08M
P/E (TTM): —
EPS (TTM): -1.90
Dividend Yield: —

Advanced Metrics

Price/Book: 1.70
PEG Ratio: —
Return on Equity: -79.91%
Return on Assets: -31.03%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 10.98
Debt/Equity: 0.02
Total Debt: $1.40M
Free Cash Flow: $-26.24M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $7.13M

KLRS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$11.76M	$11.71M	$45.04M	$30.75M
Selling, General & Admin	$2.24M	$1.76M	$6.69M	$15.40M
Operating Expenses	$14.01M	$13.46M	$51.73M	$46.15M
Operating Income	-$14.01M	-$13.46M	-$51.73M	-$46.15M
EBITDA	-$15.25M	-$14.01M	-$66.47M	-$41.98M
Pretax Income	-$15.48M	-$14.70M	-$69.17M	-$43.44M
Net Income	-$15.48M	-$14.70M	-$69.17M	-$43.44M
Diluted EPS	-11.64	-11.05	-3.70	-2.85
Diluted Shares	1.33M	1.33M	18.70M	15.27M

KLRS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$3.06M	$3.17M	$1.64M	$98.05M
Current Assets	$3.90M	$3.33M	$2.61M	$118.81M
Total Assets	$3.90M	$3.33M	$6.16M	$121.74M
Current Liabilities	$5.69M	$3.94M	$24.70M	$9.71M
Long-Term Debt	$3.25M	—	—	—
Total Debt	$3.25M	—	$19.54M	$1.45M
Total Liabilities	$34.17M	$48.35M	$102.78M	$42.92M
Retained Earnings	-$32.70M	-$47.39M	-$116.56M	-$160.00M
Shareholders' Equity	-$30.27M	-$45.02M	-$96.62M	$78.81M
Working Capital	-$1.79M	-$609.00K	-$22.10M	$109.09M
Net Debt	$194.00K	—	$17.90M	—

KLRS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$9.78M	-$14.13M	-$20.67M	-$38.37M
Capital Expenditure	—	—	—	-$200.00K
Free Cash Flow	-$9.78M	-$14.13M	-$20.67M	-$38.57M
Depreciation & Amortisation	—	—	$0.00	$13.00K
Stock-Based Compensation	$271.00K	$148.00K	$895.00K	$1.94M
Investing Cash Flow	—	—	$0.00	-$19.72M
Financing Cash Flow	$12.78M	$14.24M	$19.14M	$155.01M
Net Change in Cash	$3.00M	$110.00K	-$1.53M	$96.91M

KLRS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$6.03M	$8.44M	$9.13M	$7.16M	$7.57M
Selling, General & Admin	$4.32M	$3.82M	$3.62M	$3.64M	$4.26M
Operating Expenses	$10.35M	$12.26M	$12.74M	$10.80M	$11.83M
Operating Income	-$10.35M	-$12.26M	-$12.74M	-$10.80M	-$11.83M
EBITDA	-$8.75M	-$11.35M	-$11.89M	-$9.99M	-$10.85M
Pretax Income	-$10.20M	-$11.35M	-$11.89M	-$10.00M	-$10.86M
Net Income	-$10.20M	-$11.35M	-$11.89M	-$10.00M	-$10.86M
Diluted EPS	-2.52	-0.61	-0.64	—	-0.46
Diluted Shares	4.05M	18.70M	18.70M	—	23.72M

KLRS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$100.97M	$88.43M	$42.39M	$98.05M	$34.43M
Current Assets	$102.18M	$91.65M	$78.18M	$118.81M	$98.47M
Total Assets	$103.09M	$92.84M	$81.17M	$121.74M	$109.81M
Current Liabilities	$7.14M	$7.65M	$6.07M	$9.71M	$8.08M
Total Debt	—	—	$1.54M	$1.45M	$1.41M
Total Liabilities	$39.22M	$39.73M	$39.31M	$42.92M	$41.25M
Retained Earnings	-$126.76M	-$138.11M	-$150.00M	-$160.00M	-$170.85M
Shareholders' Equity	$63.87M	$53.12M	$41.87M	$78.81M	$68.56M
Working Capital	$95.04M	$84.00M	$72.12M	$109.09M	$90.39M

KLRS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$7.44M	-$12.54M	-$11.33M	-$7.06M	-$11.58M
Capital Expenditure	—	—	—	-$17.00K	—
Free Cash Flow	-$7.44M	-$12.54M	-$11.52M	-$7.07M	-$11.58M
Depreciation & Amortisation	$0.00	—	—	$10.00K	$10.00K
Stock-Based Compensation	$374.00K	$591.00K	$638.00K	$333.00K	$580.00K
Investing Cash Flow	$0.00	—	—	$14.98M	-$50.35M
Financing Cash Flow	$107.27M	$0.00	$0.00	$47.74M	-$1.70M
Net Change in Cash	$99.83M	-$12.54M	-$46.04M	$55.67M	-$63.63M

Market Snapshot

About

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious medical conditions. The company's pipeline typically addresses unmet medical needs in areas such as oncology, immunology, or rare diseases through innovative drug candidates. Kalaris applies modern drug discovery and development approaches to advance its therapeutic programs through clinical trials. As a development-stage company, it focuses on bringing novel treatments from research into patient care.